Background:

RR-11a is a synthetic enzyme inhibitor of Legumain.

Legumain-targeted RR-11a-coupled nanoparticles reveal high ligand-receptor affinity, enhance solid-tumor penetration and uptake by tumor cells[1].

Treatment of tumor-bearing mice with RR-11a-coupled NPs encapsulating doxorubicin results in improved tumor selectivity and drug sensitivity, leading to complete inhibition of tumor growth[1].

[1]. Liao D, et al. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine. 2011 Dec;7(6):665-73.